Concepedia

Ievgenii Karamanesht

IK

4

Publications

2K

Citations

4

H-Index

2011

Active since

Affiliations

Kyiv City Clinical Oncology Center(Current)

Hôpital Claude Huriez

Janssen (Belgium)

City Clinical Hospital

Centre Hospitalier Universitaire de Nantes

Ievgenii Karamanesht is an author at Kyiv City Clinical Oncology Center specializing in oncology, hematology, and medicine.

Top concepts

MedicineOncologyHematologyHealthPharmacotherapyRadiation OncologyPharmacologyPathologyCancer ResearchClinical Trials

Publications per year

2011–2015

4

Publications

4

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

Philippe Moreau, Halyna Pylypenko, Sebastian Grosicki et al. · The Lancet Oncology · 2011 · 910 citations

Hematological Malignancy, Oncology, Relapsed Multiple Myeloma +7

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Meletios Α. Dimopoulos, Philippe Moreau, Antonio Palumbo et al. · The Lancet Oncology · 2015 · 834 citations · Full text

Hematological Malignancy, Oncology, Dexamethasone Versus Bortezomib +8

Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma

Bertrand Arnulf, Halyna Pylypenko, Sebastian Grosicki et al. · Haematologica · 2012 · 127 citations · Full text

Hematological Malignancy, Best Response Rate, Relapsed Multiple Myeloma +14

Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma

Philippe Moreau, Ievgenii Karamanesht, Maryna Kyselyova et al. · Clinical Pharmacokinetics · 2012 · 84 citations

Hematological Malignancy, Oncology, Relapsed Multiple Myeloma +6

Rows per page

1–4 of 4